Abstract

Ex vivo expansion of hematopoietic stem and progenitor cells (HSPC) is a promising approach to improve insufficient engraftment after umbilical cord blood stem cell transplantation (UCB-SCT). Although culturing HSPC with hematopoietic cytokines results in robust proliferation, it is accompanied with extensive differentiation and loss of self-renewal capacity. Wnt signaling has been implicated in regulating HSPC fate decisions in vivo and in promoting HSPC self-renewal by inhibition of differentiation, but the effects of Wnt on the ex vivo expansion of HSPC are controversial. Here, we demonstrate that exogenous Wnt3a protein suppresses rather than promotes the expansion of UCB-derived CD34+ cells in serum free expansion cultures. The reduced expansion was also observed in cultures initiated with Lin-CD34+CD38lowCD45RA-CD90+ cells which are highly enriched in HSC and was also observed in response to activation of beta-catenin signaling by GSK3 inhibition. The presence of Wnt3a protein during the culture reduced the frequency of multilineage CFU-GEMM and the long-term repopulation ability of the expanded HSPC. These data suggest that Wnt signaling reduces expansion of human HSPC in growth factor-driven expansion cultures by promoting differentiation of HSPC.

Highlights

  • Allogeneic hematopoietic stem cell transplantation is an important part of treatment for patients suffering from hematological disorders, including leukemia, myelodysplastic syndromes, and aplastic anemia

  • To assess whether Wnt signals affect expansion of human hematopoietic stem and progenitor cells (HSPC) in culture, umbilical cord blood (UCB)-derived CD34+ cells were cultured in serum-free medium supplemented with stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (Flt3L) and TPO (SFT medium) with or without purified Wnt3a protein

  • We assessed the functionality of the cultured CD34+ cells by performing colony forming unit (CFU) assays

Read more

Summary

Introduction

Allogeneic hematopoietic stem cell transplantation is an important part of treatment for patients suffering from hematological disorders, including leukemia, myelodysplastic syndromes, and aplastic anemia. Many patients lack a suitable sibling or human leucocyte antigen (HLA) matched unrelated donor. Because of its rapid availability and less stringent matching criteria[1], umbilical cord blood (UCB) is an important alternative source for hematopoietic stem and progenitor cells (HSPC). UCB-derived HSPC significantly differ from bone marrow- and peripheral blood-derived HSPC quantitatively and qualitatively.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call